CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2026)

CRISPR Therapeutics AG has disclosed Operating Leases across 8 years of filings, most recently posting $178.9 million for Q2 2026.

• In Q2 2026, Operating Leases fell 9.38% year-over-year to $178.9 million; the TTM figure through Jun 2026 stood at $178.9 million (down 9.38% YoY), while the FY2025 annual figure was $188.2 million, down 8.84% from the prior year.
• Operating Leases came in at $178.9 million for Q2 2026 at CRISPR Therapeutics AG, down from $183.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $234.2 million in Q2 2022 to a low of $178.9 million in Q2 2026.
• Average Operating Leases over 5 years is $212.2 million, with a median of $216.9 million recorded in 2024.
• Year-over-year, Operating Leases surged 361.27% in 2022 and retreated 9.38% in 2026.
• Over 5 years, Operating Leases stood at $228.2 million in 2022, then dropped by 2.27% to $223.0 million in 2023, then dropped by 7.44% to $206.4 million in 2024, then declined by 8.84% to $188.2 million in 2025, then decreased by 4.92% to $178.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $178.9 million in Q2 2026, $183.6 million in Q1 2026, and $188.2 million in Q4 2025.